---
title: "INNOSTAR: Clinical Immunohistochemistry Laboratory has passed CAP certification"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230450770.md"
description: "INNOSTAR announced that its clinical immunohistochemistry laboratory has received certification from the College of American Pathologists (CAP), marking that the laboratory's testing quality has reached the highest international standards. As a comprehensive R&D service company providing non-clinical research services in biomedicine, this certification will enhance its market competitiveness in the clinical testing field and further expand its clinical testing business"
datetime: "2025-03-04T08:51:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230450770.md)
  - [en](https://longbridge.com/en/news/230450770.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230450770.md)
---

# INNOSTAR: Clinical Immunohistochemistry Laboratory has passed CAP certification

According to the Zhitong Finance APP, INNOSTAR (688710.SH) announced that its clinical immunohistochemistry laboratory recently received the CAP certification issued by the College of American Pathologists (CAP). CAP is considered one of the most authoritative clinical laboratory accreditation organizations internationally. Achieving CAP certification means that the laboratory's testing quality and technical standards have reached the highest international levels.

As a comprehensive research and development service (CRO) company specializing in providing non-clinical research services in biomedicine, the company offers a full range of new drug research services that comply with domestic and international application standards for pharmaceutical companies and research institutions worldwide. The CAP certification of the clinical immunohistochemistry laboratory marks the international recognition of INNOSTAR's quality management system for clinical immunohistochemistry testing and translational research, which is beneficial for the company to further enhance its market competitiveness in the clinical testing field and expand its clinical testing business. The company's competitive international service capabilities have been further improved

### Related Stocks

- [688710.CN](https://longbridge.com/en/quote/688710.CN.md)
- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)

## Related News & Research

- [Claritas Rx Strengthens Executive Team with New CRO and Two VP Promotions](https://longbridge.com/en/news/286794376.md)
- [Investeringsforeningen Nykredit Invest Balance suspender handel med udvalgte afdelinger](https://longbridge.com/en/news/286877547.md)
- [Morgans Reaffirms Their Buy Rating on Shape Australia Corporation Limited (SHA)](https://longbridge.com/en/news/286714508.md)
- [Investment bank Lincoln International raises $421 million in US IPO](https://longbridge.com/en/news/286975505.md)
- [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md)